RBN 013209
Alternative Names: RBN-013209Latest Information Update: 08 Jun 2021
At a glance
- Originator Ribon Therapeutics
- Class Antineoplastics; Heterocyclic bicyclo compounds; Small molecules
- Mechanism of Action CD38 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 10 Apr 2021 Preclinical trials in Cancer in USA (PO) in April 2021
- 10 Apr 2021 Pharmacokinetics and pharmacodynamics data from preclinical studies in Cancer presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
- 09 Apr 2021 Early research in Cancer in USA (unspecified route) prior to April 2021